Nordex's Share Price Slump Defies a Doubling in EBITDA — and Leaves Analysts at Odds

The gap between Nordex's operational trajectory and its share price performance has rarely looked wider. The wind turbine maker's stock has shed roughly 7 percent over the past month, sliding to around 37 euros, even as its second-quarter earnings delivered the kind of numbers that typically send equities higher.

That disconnect now sits at the heart of a fractured analyst debate. RBC Capital Markets and Barclays issued conflicting verdicts within 24 hours of each other this week, underscoring just how unsettled the investment community has become over the Hamburg-based company's valuation.

Two Houses, Two Conclusions

RBC lowered its price target on Nordex from 38 to 36 euros on Thursday, reaffirming an "underperform" rating that reflects a persistently cautious stance toward the stock. Barclays, arriving at a strikingly different conclusion on Friday, lifted its target from 15.80 to 35 euros — a dramatic upward adjustment, though the bank left its "equal weight" recommendation unchanged.

The Barclays revision is notable less for its destination than for its starting point. The previous target of 15.80 euros sat far below the prevailing market price, making the increase look more like a long-overdue realignment with reality than a fresh vote of confidence. Both houses now land within a euro of each other — 36 and 35 euros respectively — yet their underlying ratings convey opposing interpretations of the same evidence.

For investors, the takeaway is hardly reassuring: the question of whether recent weakness represents a buying opportunity or a justified correction after overly optimistic expectations remains unresolved among those paid to answer it.

Strong Fundamentals, Stubborn Chart

The technical picture offers little comfort. Nordex shares closed Tuesday at 37.02 euros, down 1.7 percent on the day and 3.6 percent on the week. The stock now trades roughly 28 percent below its 52-week high of 51.40 euros, set in April, and sits beneath its 50-day moving average of 40.59 euros. The relative strength index at 37 points to oversold conditions, though technicians would caution that such readings do not guarantee a reversal.

None of this weakness stems from operational deterioration. When Nordex reported second-quarter results at the end of July, the numbers were emphatic: revenue climbed 16.3 percent to approximately 2.2 billion euros, while EBITDA more than doubled from 108.2 million euros to 223.8 million euros. The corresponding margin expanded from 5.8 to 10.3 percent. Management reaffirmed its full-year guidance, citing stronger order intake and positive free cash flow.

Order momentum has continued since. Project order intake jumped 32.2 percent in the quarter to 3,054 megawatts, supplemented by US contracts exceeding 480 megawatts announced roughly three weeks ago and a 77-megawatt Romanian order in early August. Yet the share price has fallen 7.1 percent since those US orders were disclosed — evidence that individual contract announcements are currently doing little to move the needle.

Insider Buying Fails to Stem the Tide

Even a show of confidence from the executive suite could not arrest the decline. Chief Financial Officer Ilya Hartmann purchased shares at prices of 40.97 and 40.98 euros roughly three weeks ago, spending approximately 229,941 euros in total. The stock has dropped 8.3 percent since that transaction.

A broader sector signal arrived from Danish rival Vestas Wind Systems, which raised its annual guidance in mid-August following strong second-quarter results. For Nordex shareholders, that suggests demand across the wind turbine industry remains robust — even if the market has yet to reflect that resilience in Nordex's own share price.

The company has also strengthened its financial foundation, expanding its syndicated multi-currency guarantee facility to 2.475 billion euros at the end of July, with the facility now ESG-linked and offering enhanced flexibility.

A Broader Context of Contradiction

An earlier assessment from AlphaValue/Baader Europe, dating to early August, adds another layer to the picture. That house raised its rating and increased its price target, citing sustained strength in first-half order activity — a fundamental view that sits awkwardly alongside RBC's more recent skepticism.

No fresh corporate announcements — whether on orders, results, or personnel — have emerged in the past fortnight. The current debate is being driven entirely by external observers rather than new operational news from the company itself.

The longer-term record, however, remains firmly positive. Nordex shares have gained 27 percent year-to-date in 2026 and stand 82 percent higher over the past twelve months. The stock also remains well above its September low from the previous year, even after the recent retreat.

What emerges is a portrait of a company whose operational recovery is real and measurable, but whose share price is being buffeted by forces that strong earnings, insider purchases, and a steady stream of orders have so far failed to counteract. The analyst community's inability to reach a consensus view only deepens the sense that, for now, Nordex's valuation story is being written by the market's mood rather than the company's numbers.